Skip to main content

Table 1 Patient characteristics

From: Induction maintenance concept for HAART as initial treatment in HIV infected infants

Patient 1 2 3 4
Mode of delivery Caesarean (38th week) Caesarean (29th week) Caesarean Caesarean (41st week)
Prepartal prophylaxis ZDV, 3TC, NVP (5 weeks) None None None
Intrapartal prophylaxis ZDV None None None
Postnatal prophylaxis ZDV (4 weeks) 2 × NVP; ZDV + 3TC(6 weeks) None None
Age at diagnosis 4 weeks 5 months 2.5 months 4.5 months
Initial HIV-1 RNA load (copies/ml) 500 000 16 000 139 670 3 600 000
Initial CD4 cell count (absolute cells, μl/%) 3732/44 2515/43 1093/17 330/6
Initial CD4 cell count (ARP, %) 106 100 44 13
4 drug HAART ABC, 3TC, LPV, NVP ABC, 3TC, LPV, NVP ZDV, 3TC, NFV, NVP ZDV, 3TC, LPV, NVP
Maximal decline of viral load (log change and duration) 5 log; 4.5 months 4 log; 2 months 5 log; 2 months 5 log; 6 months
Duration of 4 drug HAART 11 months 13 months 13 months 10 months
Clinical toxicity *Atopic dermatitis None None None
Laboratory toxicity AST (1.4 × ULN - Grade 1);
AP (2.2 × ULN -Grade 1);
Cholesterol (235 mg/dl - Grade 2);
*GGT (18.6 × ULN)
AP (1,4 × ULN - Grade 1);
CK (4.2 × ULN - Grade 1);
*GGT (2.1 × ULN)
AP (1,2 × ULN - Grade); CK (2.2 × ULN - Grade 0), *GGT (7.2 × ULN) AP (1.8 × ULN - Grade 1);
CK (2.4 × ULN - Grade 0);
*GGT(27 × ULN);
Triglycerides (498 mg/dl - Grade 1)
3 drug HAART ABC, 3TC, NVP ABC, 3TC, NVP ZDV, 3TC, NVP ZDV, 3TC, NVP
Viral load at last visit (copies/ml) 16801 < 1 < 1 48
Follow up time 50 months 50 months 34 months 27,5 months
  1. Antiretroviral drugs: Abacavir (ABC), Lamivudine (3TC), Lopinavir (LPV), Nelfinavir (NFV), Nevirapine (NVP), Zidovudine (ZDV); Adverse effects were graded according to DAIDS (Division of AIDS, NIH), ULN = upper limit of normal, *no DAIDS criteria; elevated 4 weeks after switching to a triple drug regime